The bradykinin B2 receptor antagonist Icatibant (HOE 140) corrects avid Na+ retention in rats with CCl4-induced liver cirrhosis: possible role of enhanced microvascular leakage.

摘要: Abstract Avid Na + retention is a hallmark of liver cirrhosis. The aim this study was to investigate whether and how bradykinin involved in rats with CCl 4 -induced To end the B 2 receptor antagonist Icatibant (HOE 140) used. On one hand, has renal natriuretic action. other potent mediator both vasodilation microvascular leakage. Both vascular mechanisms, which are reported for cirrhosis, could cause underfilling by activating renin–angiotensin–aldosterone system. normalised reduced hyperactivity system, suggesting bradykinin-induced disturbance. had no significant effect on mild hypotension developed treatment. However, there indirect evidence enhanced leakage that strongly inhibited Icatibant. Our experimental results demonstrate key cirrhosis suggest increase mainly responsible.